Twist Bioscience Stock Price, News & Analysis

Twist Bioscience (TWST) has announced a strategic collaboration with Sosei Heptares to develop therapeutic antibodies targeting G protein-coupled receptors (GPCRs). This partnership combines Twist's synthetic antibody libraries and bioinformatics with Sosei Heptares' StaR® platform. Sosei Heptares will hold exclusive rights to develop and commercialize identified antibody leads. Twist will receive upfront payments, ongoing R&D costs, and milestone payments, though specific financial terms are not disclosed. This alliance aims to expand opportunities in GPCR-targeted antibody therapeutics, addressing a significant area in drug development.

Twist Bioscience Corporation (NASDAQ: TWST) announced the availability of synthetic RNA positive controls for the SARS-CoV-2 Omicron variants, aiding in pandemic response. As of December 6, 2021, Omicron has been confirmed in over 50 countries, prompting the need for effective diagnostics and therapeutic development. CEO Emily M. Leproust emphasized the company's commitment to developing tools to combat COVID-19 variants. Twist also offers a suite of next-generation sequencing tools and is working on controls for the BA.2 variant. The company adheres to strict biosecurity protocols for customer purchases.

Twist Bioscience Corporation (NASDAQ: TWST) has launched the Twist cfDNA Pan-cancer Reference Standards, a revolutionary control for liquid biopsy tests aimed at enhancing cancer detection accuracy. This synthetic DNA product mimics real human-derived cell-free DNA and supports the development of ultra-sensitive ctDNA assays. With over 400 variants, it enables precise detection and tracking in cancer diagnostics. CEO Emily Leproust emphasizes its potential to advance clinical insights in oncology. The innovation follows the success of their SARS-CoV-2 controls.

Twist Bioscience Corporation (NASDAQ: TWST) announced that Steffen Hellmold will participate in the SRC-SIA Webinar on December 9, 2021, discussing the Decadal Plan for Semiconductors and emerging storage technologies, including DNA Data Storage.

This innovative technology promises over 100,000 times higher storage density compared to traditional methods, aiming to address the growing demand for sustainable and efficient long-term data storage solutions.

SOUTH SAN FRANCISCO, Calif. – Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust will present at two upcoming virtual investor conferences. The first is the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 29 at 10:00 a.m. ET, followed by the Evercore ISI HealthCONx Conference on November 30 at 10:30 a.m. ET. Investors can access the fireside chats via the company’s Investor Calendar page. Twist is a leader in synthetic biology, specializing in high-quality synthetic DNA for various industries.

Twist Bioscience reported record revenues for fiscal 2021 at $132.3 million, marking a 47% increase from $90.1 million in fiscal 2020. Growth is attributed to strong performance in SynBio, NGS, and Biopharma sectors. The company expects revenues of $183 million to $193 million for fiscal 2022. Despite the revenue growth, the net loss widened to $152.1 million, or $3.15 per share. The company had $477.9 million in cash as of September 30, 2021, supporting future investments in biopharma and data storage.

Twist Bioscience Corporation (NASDAQ: TWST) announced the acquisition of Abveris, a private company specializing in in vivo antibody discovery, for up to $190 million. The deal consists of $150 million in common stock and cash at closing, with up to $40 million contingent on Abveris meeting revenue targets. This acquisition aims to enhance Twist's capabilities in antibody design and discovery, integrating various methods including synthetic libraries and AI. A conference call is scheduled for 8:00am ET to discuss further details.

Twist Bioscience Corporation (NASDAQ: TWST) has announced an extension of its partnership with Invetx, focused on developing monoclonal antibodies for animal health. This new phase incorporates next-generation synthetic antibody phage display technology to discover innovative therapeutic candidates for diseases affecting dogs and cats. The collaboration aims to enhance antibody optimization through complementary in vitro capabilities, complementing Invetx’s in vivo platforms. Twist’s extensive synthetic antibody libraries are already in use to identify potential drug candidates for various veterinary applications.

Twist Bioscience Corporation (NASDAQ: TWST) announced the launch of Revelar Biotherapeutics, Inc., an independent biotechnology company focused on developing an antibody that neutralizes all known SARS-CoV-2 variants. Revelar will utilize Twist Biopharma's antibody discovery platform, with potential for licensing up to five additional therapeutics in four years. Twist is set to receive over $100 million in milestone payments and royalties from Revelar. Investment of up to $10 million from Twist is also planned, alongside significant minority ownership in Revelar.